Glucotrack, INC 8-K filings

Glucotrack's implantable continuous glucose monitor successfully completed the first 30 days of a 60-day preclinical study, demonstrating accurate glucose tracking in the epidural space.

Glucotrack, Inc. has announced a 1-for-5 reverse stock split of its common stock, effective May 20, 2024, to meet Nasdaq's minimum bid price requirement.

GlucoTrack, Inc. held its 2024 Annual Meeting of Stockholders, where key proposals including the approval of a new equity incentive plan, the election of directors, and a reverse stock split were passed.

GlucoTrack, Inc. exchanged common stock purchase warrants for 3,593,203 shares of common stock on February 13, 2024.

GlucoTrack, Inc. has released an investor presentation on its website, which it may use in whole or in part for presentations to investors and analysts.